Overview

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study was to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered to participants with non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

atezolizumab
Tiragolumab